Proposed Special Review Decision PSRD2020-04, Special Reviews of Pymetrozine and Its Associated End-use Products
Before making a special review decision on pymetrozine, Health Canada will consider all comments received from the public in response to PSRD2020-04. A science-based approach will be applied in making a final decision on pymetrozine. Health Canada will then publish a special review decision document, which will include the decision, the reasons for it, a summary of the comments received on the proposed decision, and Health Canada’s response to these comments.
- Publisher - Current Organization Name: Health Canada
- Licence: Open Government Licence - Canada